大麻素衍生产品是一种潜在的新型治疗药物,用于乳头甲状腺癌
Carolina Taico Oliva1, Ibrahim Musa1, Fariba Ardalani1
1New York Medical College, Valhalla, USA.
Integrative cancer therapies
|July 24, 2025
概括
一种大麻素产物BRF1A降低了乳头甲状腺癌细胞活力. 它还调节了关键基因表达,对TP53进行上调和对K1细胞中的BCL-2和c-Myc进行下调.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳头甲状腺癌 (PTC) 是最常见的内分泌恶性瘤,主要影响女性.
- 目前的治疗方法如甲状腺切除术提供了良好的预后,但正在进行非侵入性治疗研究.
- 来自转移性PTC的K1细胞系作为研究新疗法的模型.
研究的目的:
- 研究一种基于大麻素的产品BRF1A对K1 PTC细胞系的抗癌作用.
- 确定BRF1A对TP53,c-Myc和BCL-2基因表达的影响.
- 探索潜在的非侵袭性治疗策略,用于区分良好的甲状腺癌.
主要方法:
- 在24小时和48小时内,K1 PTC细胞与BRF1A共同培养.
- 细胞活力使用试蓝色排除试验进行了评估.
- 使用定量实时PCR (qRT-PCR) 测量TP53,c-Myc和BCL-2基因的表达水平.
主要成果:
- BRF1A 显示了 K1 PTC 细胞活力的剂量和时间依赖性下降.
- 在24小时内,BRF1A显著增加了TP53基因表达.
- BRF1A治疗导致K1细胞中BCL-2和c-Myc基因表达的减少.
结论:
- 大麻素产品BRF1A作为一种潜在的调节者,在高度分化的甲状腺癌中起作用.
- BRF1A可以调节p53并降低BCL-2和c-Myc的调节,这表明一种抗癌机制.
- 需要进一步的体外和体内研究来阐明PTC中BRF1A的精确机制和治疗潜力.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
368
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
368
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
Cancer Vaccines
514
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
514
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


